Key result
Early clinical diagnosis and treatment of varicella-zoster virus myocarditis can lead to better outcomes and reduce associated mortality.
Why the study?
VZV is usually self-limiting but can cause severe complications like myocarditis, prompting investigation into its early clinical diagnosis and the efficacy of the VZV vaccine in preventing myocarditis.
Does early clinical diagnosis and treatment reduce mortality in patients with varicella-zoster virus myocarditis?
Systematic Review (n=13)
Does early clinical diagnosis and treatment reduce mortality in patients with varicella-zoster virus myocarditis?
Early clinical diagnosis and treatment of VZV myocarditis, a rare but severe complication, is crucial for reducing associated morbidity and mortality.
Supports urgent evaluation in suspected VZV myocarditis; extends sparse case evidence via systematic synthesis.
Varicella-zoster virus (VZV) is a viral infection that causes chickenpox and shingles. Although it is usually self-limiting, it can lead to severe complications, especially in pediatric and immunocompromised patients. VZV was first discovered as a cause of myocarditis in 1953. In this review article, we aim to investigate the early clinical diagnosis of myocarditis in VZV infections and the efficacy of the VZV vaccine in preventing myocarditis. The literature search was done using PubMed, Google Scholar, and Sci-Hub databases. A high VZV mortality rate was noted among adults, infants, and immunocompromised patients. The early diagnosis and treatment of VZV myocarditis can reduce mortality.
No takes yet. Share an insight, caveat, or question.
Cherukuri et al. (2023) conducted a systematic review in Varicella-Zoster Virus Myocarditis (n=13). Varicella-Zoster Virus (VZV) infection was evaluated. Early clinical diagnosis and treatment of varicella-zoster virus myocarditis can lead to better outcomes and reduce associated mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: